| 8.9 0.35 (4.09%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.28 |
1-year : | 13.17 |
| Resists | First : | 9.65 |
Second : | 11.28 |
| Pivot price | 8.75  |
|||
| Supports | First : | 8.3 |
Second : | 7.46 |
| MAs | MA(5) : | 8.58 |
MA(20) : | 8.64 |
| MA(100) : | 8 |
MA(250) : | 6.97 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 44.2 |
D(3) : | 43.6 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 9.65 | Low : | 4.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MGTX ] has closed below upper band by 33.3%. Bollinger Bands are 37.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.17 - 9.21 | 9.21 - 9.24 |
| Low: | 8.19 - 8.23 | 8.23 - 8.27 |
| Close: | 8.83 - 8.9 | 8.9 - 8.96 |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Tue, 11 Nov 2025
Piper Sandler Raises Price Target for MGTX to $30, Maintains Ove - GuruFocus
Tue, 11 Nov 2025
MeiraGTx stock price target raised to $30 by Piper Sandler on Eli Lilly deal - Investing.com
Tue, 11 Nov 2025
MGTX: Chardan Capital Maintains Buy Rating and $35 Price Target - GuruFocus
Tue, 11 Nov 2025
Time To Eye MeiraGTx As Shares Hit New 52-Week High? - RTTNews
Mon, 10 Nov 2025
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? - MSN
Mon, 10 Nov 2025
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -71 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8.045e+007 (%) |
| Held by Institutions | 3.177e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.007e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.03 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 213.5 % |
| Return on Equity (ttm) | -42.5 % |
| Qtrly Rev. Growth | 3.792e+007 % |
| Gross Profit (p.s.) | 139.92 |
| Sales Per Share | -171.54 |
| EBITDA (p.s.) | 7.4127e+006 |
| Qtrly Earnings Growth | -1.4532e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -4.39 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0 |
| Dividend | 3.59e+006 |
| Forward Dividend | 3.69e+006 |
| Dividend Yield | 40337100% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|